Johnson & Johnson’s one-shot vaccine prevents 66% of moderate to severe cases of Covid-19, according to Bloomberg. In a more than 44,000-person study, the vaccine was also found to stop 85% of severe infections and 100% hospitalizations and deaths.
- The high effectiveness of the J&J vaccine generates hopes that it can reshape a challenging inoculation campaign and alleviate stress and suffering caused by the pandemic.
- Following the results, J&J plans to file for an emergency-use authorization in the U.S. next week and expects clearance in March.
- Unlike vaccines from Moderna and Pfizer, which requires two shots and must be kept frozen, J&J needs one shot and can be kept in a refrigerator for three months.
- J&J vaccine trials were less effective against the new coronavirus variants, with the vaccine only 57% effective against the South African variant and 66% effective in Latin America.
- J&J is also working on next-generation versions of the vaccine shot that could protect against certain coronavirus variants
- The company targets a total of seven manufacturing facilities by the end of the second quarter and said it is on course to hit the goal of producing 1 billion doses globally before year-end.
Johnson & Johnson stock is currently declining. JNJ: NYSE is down 3.40%